What are the well-known manufacturers of adalimumab?

Adalimumab (Adalimumab), as an important anti-TNF-α biological agent, was originally developed and marketed by the American company AbbVie (AbbVie). Its original trade name is "Humira". As one of the best-selling biologic drugs in the world, Humira has long dominated the global market and has become a core drug for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis and other autoimmune diseases. As its core patents expire in many countries, more and more well-known pharmaceutical companies have begun to develop and produce generic versions of it, so-called biosimilars. This has also led to an increase in the number of adalimumab manufacturers and the gradual diversification of the global supply system.

In the international market, in addition to the original research manufacturer AbbVie, SamsungBioepis cooperated with Bristol-Myers Squibb (BMS) to launch an adalimumab biosimilar called "Imraldi"; Pfizer also launched "Amgevita" through its subsidiary Hospira; AstraZeneca's MedImmune and Merck jointly launched "Idacio"; Germany's Boehringer (Boehringer) Ingelheim) developed "Cyltezo". Most of these products have been approved in Europe and the United States and are widely used in clinical settings, effectively reducing treatment costs and expanding the number of drug users.

In the Chinese market, in addition to the imported original drug "Humira" has been included in the national medical insurance directory, many well-known domestic companies have successfully developed and put into production the domestic version of adalimumab. Representative companies include Henlius, whose product "Handayuan" was approved for marketing by the State Food and Drug Administration in 2020 and is one of the first domestic biosimilar drugs; Qilu Pharmaceutical's "Aputo" has also been successfully launched and has been highly recognized in terms of drug quality and bioequivalence; Innovent Biologics, Hisun Pharmaceuticals, etc. are also in the field and have launched products with relatively more advantageous prices.

Reference materials:https://www.drugs.com/adalimumab.html